{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:09:39Z","timestamp":1768439379396,"version":"3.49.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5P30 GM106392"],"award-info":[{"award-number":["5P30 GM106392"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Akira Arimura Foundation"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.peptides.2017.07.007","type":"journal-article","created":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T18:48:23Z","timestamp":1500144503000},"page":"25-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice"],"prefix":"10.1016","volume":"95","author":[{"given":"Venkat","family":"Subramaniam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gin","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Burn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome L.","family":"Maderdrut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Coy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt J.","family":"Varner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2017.07.007_bib0005","first-page":"194","article-title":"Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model","volume":"52","author":"Alderton","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.peptides.2017.07.007_bib0010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.nbd.2008.06.014","article-title":"PACAP prevents toxicity induced by cisplatin in rat and primate neurons but not in proliferating ovary cells: involvement of the mitochondrial apoptotic pathway","volume":"32","author":"Aubert","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.peptides.2017.07.007_bib0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10637-007-9037-8","article-title":"(BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone","volume":"25","author":"Cavalletti","year":"2007","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.peptides.2017.07.007_bib0020","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1749-6632.1996.tb17502.x","article-title":"Analysis of cardiovascular responses to PACAP-27, PACAP-38, and vasoactive intestinal polypeptide","volume":"805","author":"Champion","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.peptides.2017.07.007_bib0025","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1212\/WNL.0b013e31828cf891","article-title":"Mitoxantrone-related acute leukemia in MS: an open or closed book","volume":"80","author":"Chan","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.peptides.2017.07.007_bib0030","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000127124","article-title":"Effects of intravenously infused pituitary adenylate cyclase-activation polypeptide on adrenohypophyseal hormone secretion in normal men","volume":"64","author":"Chiodera","year":"1996","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.peptides.2017.07.007_bib0035","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/14737175.2014.915742","article-title":"The current role of mitoxantrone in the treatment of multiple sclerosis","volume":"14","author":"Cocco","year":"2014","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.peptides.2017.07.007_bib0040","series-title":"Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs as adjunctive treatments with inhibitors of calcineurin or inhibitors of the mammalian target of rapamycin (mTOR) complexes","author":"Coy","year":"2011"},{"key":"10.1016\/j.peptides.2017.07.007_bib0045","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/msj.20239","article-title":"Current disease-modifying treatment of multiple sclerosis","volume":"78","author":"Derwenskus","year":"2011","journal-title":"Mt. Sinai J. Med."},{"key":"10.1016\/j.peptides.2017.07.007_bib0050","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/jcbfm.2008.131","article-title":"Isolation of peptide transport system-6 from brain endothelial cells: therapeutic effects with antisense inhibition in Alzheimer and stroke models","volume":"29","author":"Dogrukol-Ak","year":"2009","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.peptides.2017.07.007_bib0055","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/bjc.1989.314","article-title":"The role of reductive and oxidative metabolism in the toxicity of mitoxantrone, adriamycin and menadione in human liver derived Hep G2 hepatoma cells","volume":"60","author":"Duthie","year":"1989","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.peptides.2017.07.007_bib0060","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.nbd.2014.08.017","article-title":"Novel therapeutic strategy for neurodegeneration by blocking A\u00df seeding mediated aggregation in models of Alzheimer\u2019s disease","volume":"74","author":"Eleuteri","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.peptides.2017.07.007_bib0065","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/med.21364","article-title":"Mitoxantrone, more than just another topoisomerase II poison","volume":"36","author":"Evison","year":"2016","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.peptides.2017.07.007_bib0070","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2165\/00003495-199141030-00007","article-title":"A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer","volume":"41","author":"Faulds","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2017.07.007_bib0075","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/eji.200535430","article-title":"Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis","volume":"36","author":"Fernandez-Martin","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.peptides.2017.07.007_bib0080","first-page":"3093","article-title":"Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans","volume":"82","author":"Filipsson","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2017.07.007_bib0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/009286150103500134","article-title":"Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999","volume":"35","author":"Fung","year":"2001","journal-title":"Drug Inf. J."},{"key":"10.1016\/j.peptides.2017.07.007_bib0090","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.peptides.2005.06.022","article-title":"Pituitary adenylate cyclase activating polypeptide protects cardiomyocytes against oxidative stress-induced apoptosis","volume":"2","author":"Gasz","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2017.07.007_bib0095","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1196\/annals.1317.029","article-title":"PACAP inhibits oxidative stress-induced activation of MAP kinase-dependent apoptotic pathway in cultured cardiomyocytes","volume":"1070","author":"Gasz","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.peptides.2017.07.007_bib0100","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2353\/ajpath.2006.051081","article-title":"Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses","volume":"168","author":"Gonzalez-Rey","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.peptides.2017.07.007_bib0105","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1677\/joe.0.1370529","article-title":"Vasoactive intestinal peptide, but not pituitary adenylate cyclase-activating peptide, modulates the responsiveness of the gonadotroph to LHRH in man","volume":"137","author":"Hammond","year":"1993","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.peptides.2017.07.007_bib0110","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.neurobiolaging.2014.03.022","article-title":"Pituitary adenylate cyclase-activating polypeptide protects against \u03b2-amyloid toxicity","volume":"35","author":"Han","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.peptides.2017.07.007_bib0115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0031-6997(24)01360-7","article-title":"International Union of Pharmacology: XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide","volume":"50","author":"Harmar","year":"1998","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.peptides.2017.07.007_bib0120","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1476-5381.2012.01871.x","article-title":"Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR Review 1","volume":"166","author":"Harmar","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.peptides.2017.07.007_bib0125","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2017.07.007_bib0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jneuroim.2003.12.008","article-title":"The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) modulate several biochemical pathways in human leukemic myeloid cells","volume":"149","author":"Hayez","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.peptides.2017.07.007_bib0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.tips.2013.11.001","article-title":"Insights into the structure of class B GPCRs","volume":"35","author":"Hollenstein","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.peptides.2017.07.007_bib0140","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/hep.25802","article-title":"Neuropeptide PACAP in mouse liver ischemia and reperfusion injury: immunomodulation via cAMP-PKA pathway","volume":"57","author":"Ji","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.peptides.2017.07.007_bib0145","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/icb.2010.29","article-title":"New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes","volume":"88","author":"Jimeno","year":"2010","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.peptides.2017.07.007_bib0150","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1191\/1352458504ms1096oa","article-title":"Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells","volume":"10","author":"Kato","year":"2004","journal-title":"Mult. Scler."},{"key":"10.1016\/j.peptides.2017.07.007_bib0155","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.peptides.2012.09.023","article-title":"Delayed administration of pituitary adenylate cyclase-activating polypeptide 38 ameliorates renal ischemia\/reperfusion injury in mice by modulating Toll-like receptors","volume":"38","author":"Khan","year":"2012","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2017.07.007_bib0160","doi-asserted-by":"crossref","first-page":"e00163","DOI":"10.1002\/phy2.163","article-title":"Pituitary adenylate cyclase-activating polypeptide prevents contrast-induced nephropathy in a novel mouse model","volume":"1","author":"Khan","year":"2013","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.peptides.2017.07.007_bib0165","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1212\/WNL.0b013e3181e0f7e6","article-title":"Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS","volume":"74","author":"Kingwell","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.peptides.2017.07.007_bib0170","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1096\/fj.05-4812fje","article-title":"The neuropeptide PACAP promotes the \u03b1-secretase pathway for processing the Alzheimer amyloid precursor protein","volume":"20","author":"Kojro","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.peptides.2017.07.007_bib0175","first-page":"815","article-title":"The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study","volume":"22","author":"Koutinos","year":"2002","journal-title":"Anticancer Res."},{"key":"10.1016\/j.peptides.2017.07.007_bib0180","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2","article-title":"A clinicopathologic analysis of adriamycin cardiotoxicity","volume":"32","author":"Lefrak","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.peptides.2017.07.007_bib0185","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/S0196-9781(01)00567-8","article-title":"Characterization of functional VIP\/PACAP receptors in the human erythroleukemic HEL cell line","volume":"22","author":"Lema-Kisoka","year":"2001","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2017.07.007_bib0190","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1158\/0008-5472.CAN-05-2809","article-title":"Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells","volume":"66","author":"Li","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.peptides.2017.07.007_bib0195","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.peptides.2007.05.002","article-title":"Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study","volume":"28","author":"Li","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2017.07.007_bib0200","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.regpep.2007.09.012","article-title":"Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases","volume":"145","author":"Li","year":"2008","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2017.07.007_bib0205","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12031-010-9394-1","article-title":"Pituitary adenylate cyclase-activating polypeptide prevents cisplatin-induced renal failure","volume":"43","author":"Li","year":"2010","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.peptides.2017.07.007_bib0210","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm9013407","article-title":"Mitoxantrone analogues as ligands for a stem-loop structure of tau pre-mRNA","volume":"52","author":"Liu","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.peptides.2017.07.007_bib0215","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0891-5849(90)90071-P","article-title":"Myocardial damage induced by doxorubicins: hydroperoxide-initiated chemiluminescence and morphology","volume":"8","author":"Llesuy","year":"1990","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.peptides.2017.07.007_bib0220","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cvr\/cvq043","article-title":"Oxidative stress contributes to methamphetamine-induced left ventricular dysfunction","volume":"87","author":"Lord","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.peptides.2017.07.007_bib0225","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0300-483X(93)90135-F","article-title":"Oxidative stress in mouse heart by antitumoral drugs: a comparative study of doxorubicin and mitoxantrone","volume":"29","author":"Lores Arnaiz","year":"1993","journal-title":"Toxicology"},{"key":"10.1016\/j.peptides.2017.07.007_bib0230","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1212\/WNL.0b013e3181a8164c","article-title":"Cyclophosphamide therapy in pediatric multiple sclerosis","volume":"72","author":"Makhani","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.peptides.2017.07.007_bib0235","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10072-009-0142-7","article-title":"Mitoxantrone: benefits and risks in multiple sclerosis patients","volume":"30","author":"Martinelli","year":"2009","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.peptides.2017.07.007_bib0240","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0006-291X(89)91757-9","article-title":"Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells","volume":"164","author":"Miyata","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.peptides.2017.07.007_bib0245","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1253\/circj.CJ-09-1024","article-title":"Cardioprotective effect of endogenous pituitary adenylate cyclase-activating polypeptide on doxorubicin-induced cardiomyopathy in mice","volume":"74","author":"Mori","year":"2010","journal-title":"Circ. J."},{"key":"10.1016\/j.peptides.2017.07.007_bib0250","doi-asserted-by":"crossref","first-page":"E853","DOI":"10.1152\/ajpendo.00152.2006","article-title":"Pituitary adenylate cyclase-activating peptide affects homeostatic sleep regulation in healthy young men","volume":"292","author":"Murck","year":"2007","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2017.07.007_bib0255","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.peptides.2012.05.021","article-title":"Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins","volume":"36","author":"Nonaka","year":"2012","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2017.07.007_bib0260","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1046\/j.1432-1327.2000.01606.x","article-title":"Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity","volume":"267","author":"O'Brien","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.peptides.2017.07.007_bib0265","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/S0196-9781(02)00085-2","article-title":"The neuropeptide PACAP attenuates \u03b2-amyloid (1\u201342)-induced toxicity in PC12 cells","volume":"23","author":"Onoue","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2017.07.007_bib0270","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12031-010-9415-0","article-title":"Development of PACAP38 analogue with improved stability: physicochemical and in vitro\/in vivo pharmacological characterization","volume":"43","author":"Onoue","year":"2011","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.peptides.2017.07.007_bib0275","first-page":"841","article-title":"Myocardial effects of mitoxantrone and doxorubicin in the mouse and guinea pig","volume":"68","author":"Perkins","year":"1984","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.peptides.2017.07.007_bib0280","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.regpep.2007.09.015","article-title":"PKA-Bad-14-3-3 and Akt-Bad-14-3-3 signaling pathways are involved in the protective effects of PACAP against ischemia\/reperfusion-induced cardiomyocyte apoptosis","volume":"145","author":"R\u00e1cz","year":"2008","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2017.07.007_bib0285","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12031-010-9349-6","article-title":"Protective effect of PACAP against doxorubicin-Induced cell death in cardiomyocyte culture","volume":"42","author":"Racz","year":"2010","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.peptides.2017.07.007_bib0290","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1096\/fj.10-180133","article-title":"Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice","volume":"9","author":"Rat","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.peptides.2017.07.007_bib0295","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/01.STR.31.6.1411","article-title":"Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat","volume":"31","author":"Reglodi","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.peptides.2017.07.007_bib0300","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/cei.12206","article-title":"Requirement for safety monitoring for approved multiple sclerosis therapies: an overview","volume":"175","author":"Rommer","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.peptides.2017.07.007_bib0305","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1203\/00006450-199309000-00017","article-title":"Pituitary adenylate cyclase activating polypeptide: a neuropeptide with potent inotropic and coronary vasodilatory effects in neonatal pig hearts","volume":"34","author":"Ross-Ascuitto","year":"1993","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.peptides.2017.07.007_bib0310","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12012-013-9230-2","article-title":"Mitochondrial cumulative damage induced by mitoxantrone: late onset cardiac energetic impairment","volume":"14","author":"Rossato","year":"2013","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.peptides.2017.07.007_bib0315","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0167-0115(02)00193-3","article-title":"The effect of pituitary adenylate cyclase activating polypeptide on cultured rat cardiocytes as a cardioprotective factor","volume":"109","author":"Sano","year":"2002","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2017.07.007_bib0320","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1365-2036.2009.03999.x","article-title":"Clinical trial: cyclophosphamide pulse therapy \u2212 a promising therapeutic alternative in refractory Crohn's disease","volume":"29","author":"Schmidt","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.peptides.2017.07.007_bib0325","first-page":"595","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years., EMBO","volume":"8","author":"Selkoe","year":"2016","journal-title":"Mol. Med."},{"key":"10.1016\/j.peptides.2017.07.007_bib0330","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1073\/pnas.0812257106","article-title":"Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis","volume":"106","author":"Tan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.peptides.2017.07.007_bib0335","doi-asserted-by":"crossref","first-page":"e61200","DOI":"10.1371\/journal.pone.0061200","article-title":"Pituitary adenylate cyclase activating peptide deficient mice exhibit impaired thymic and extrathymic regulatory T cell proliferation during EAE","volume":"8","author":"Tan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.peptides.2017.07.007_bib0340","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/hep.25902","article-title":"Pituitary adenylate cyclase-activating polypeptide: a neuromodulator of hepatic ischemia-reperfusion injury","volume":"57","author":"Tsung","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.peptides.2017.07.007_bib0345","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1124\/pr.109.001370","article-title":"Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 Years after the discovery","volume":"61","author":"Vaudry","year":"2009","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.peptides.2017.07.007_bib0350","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1124\/dmd.106.013474","article-title":"Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines","volume":"35","author":"Vibet","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.peptides.2017.07.007_bib0355","first-page":"83","article-title":"Pituitary adenylate cyclase activation polypeptide is a potent vasodilator in humans","volume":"20","author":"Warren","year":"1992","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.peptides.2017.07.007_bib0360","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/bph.12181","article-title":"PACAP: neuropeptide modulators of CNS inflammation, injury, and repair","volume":"169","author":"Waschek","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.peptides.2017.07.007_bib0365","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1074\/jbc.R800013200","article-title":"Tau mutations in neurodegenerative diseases","volume":"284","author":"Wolfe","year":"2009","journal-title":"J. Biol. Chem."}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978117302279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978117302279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T23:33:40Z","timestamp":1750635220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978117302279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":73,"alternative-id":["S0196978117302279"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2017.07.007","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2017.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}